

Applicant/PHCR: AUROGEN SA (PTY) LTD
Product proprietary name: LYNERIG
Dosage form and strength Each capsule contains 25/75/150 mg of Pregabalin respectively.
Date of approval -21 August 2023

PROPOSED PATIENT INFORMATION LEAFLET

SCHEDULING STATUS

S5

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

LYNERIG 25 mg

LYNERIG 75 mg

LYNERIG 150 mg

Pregabalin.

Sugar free.

Read all of this leaflet carefully before you start taking LYNERIG

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- **LYNERIG** has been prescribed for you personally and you should not share your medicine with other people. It may harm them, even if their symptoms are the same as yours.

What is in this leaflet:

1. What **LYNERIG** is and what it is used for.

Applicant/PHCR: AUROGEN SA (PTY) LTD
Product proprietary name: LYNERIG
Dosage form and strength Each capsule contains 25/75/150 mg of Pregabalin respectively.
Date of approval -21 August 2023

2. What you need to know before you use LYNERIG .
3. How to use **LYNERIG**.
4. Possible side effects.
5. How to store **LYNERIG** .
6. Contents of the pack and other information.

1. What LYNERIG is and what it is used for

LYNERIG belongs to a group of medicines used to treat neuropathic pain due to Herpes zoster infections and diabetes in adults.

2. What you need to know before you take LYNERIG

Do not take LYNERIG :

If you are allergic to pregabalin or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Take special care with LYNERIG :

- If you start taking **LYNERIG** and experience swelling of the face, lips, tongue, and throat, as well as diffuse skin rash. These are symptoms of an allergic reaction, and you should contact your healthcare practitioner immediately.
- If you are taking diabetes medicine and gain weight whilst taking **LYNERIG** talk to your doctor as he/she may need to alter the dose of your diabetes medicine.
- **LYNERIG** can cause dizziness and somnolence, which can increase the occurrence of accidental injury. You should be extra cautious when taking **LYNERIG** until you are used to how you react to it.

Applicant/PHCR: AUROGEN SA (PTY) LTD
Product proprietary name: LYNERIG
Dosage form and strength Each capsule contains 25/75/150 mg of Pregabalin respectively.
Date of approval -21 August 2023

- **LYNERIG** may cause blurring or loss of vision, or other changes in eyesight, many of which are temporary. You should immediately tell your doctor if you experience any changes in your vision.
- **LYNERIG** can cause kidney failure in some patients. If you experience decreased urination whilst taking **LYNERIG** you should tell your doctor.
- Stopping treatment with **LYNERIG** after short- and long-term use may cause withdrawal symptoms such as: difficulty sleeping, headache, nausea, anxiety, diarrhoea, flu syndrome, nervousness, depression, pain, convulsion, excessive sweating and dizziness.
- If you suffer from or have a family history of heart disease you tell your doctor, before commencing treatment with **LYNERIG**.
- If you start treatment with **LYNERIG** and have thoughts of harming or killing yourself, you should immediately tell your doctor.
- **LYNERIG**, when taken with other medicines (certain pain medicines) may cause gastrointestinal problems (e.g. constipation, blocked or paralysed bowel). Tell your doctor if you experience constipation, especially if you are prone to this problem.
- Before taking **LYNERIG** you should tell your doctor if you have a history of alcoholism or any drug abuse or dependence. Do not take more medicine than prescribed.
- Tell your doctor if you have a history of any serious medical conditions, including liver or kidney disease, because taking **LYNERIG** while suffering from such conditions

Applicant/PHCR: AUROGEN SA (PTY) LTD
Product proprietary name: LYNERIG
Dosage form and strength Each capsule contains 25/75/150 mg of Pregabalin respectively.
Date of approval -21 August 2023

Other medicines with LYNERIG :

Always tell your healthcare professional if you are taking any other medicine (this includes complementary or traditional medicines).

LYNERIG interacts with the following medicines:

- Oxycodone – (used as a pain-killer)
- Lorazepam – (used for treating anxiety)
- Alcohol

Taking the above with **LYNERIG** may lead to excess dizziness, sleepiness and decreased concentration which could lead to respiratory failure, coma and death.

LYNERIG with food, drink and alcohol

There are no noted interactions between food

Applicant/PHCR: AUROGEN SA (PTY) LTD
Product proprietary name: LYNERIG
Dosage form and strength Each capsule contains 25/75/150 mg of Pregabalin respectively.
Date of approval -21 August 2023

Pregnancy, breastfeeding and fertility

Pregnancy

LYNERIG should not be taken during pregnancy or when breastfeeding, unless you are told otherwise by your doctor. Effective contraception must be used by women of child-bearing potential.

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, please consult your doctor, pharmacist or other healthcare professional for advice before taking this medicine.

Driving and using machines

LYNERIG may cause dizziness, sleepiness and decreased concentration. Head and body injuries and road traffic incidents have been reported with **LYNERIG**. You should not drive, operate complex machinery or engage in other potentially hazardous activities until you know whether **LYNERIG** affects your ability to perform these activities

3. How to take LYNERIG

Do not share medicines prescribed for you with any other person.

Applicant/PHCR: AUROGEN SA (PTY) LTD
Product proprietary name: LYNERIG
Dosage form and strength Each capsule contains 25/75/150 mg of Pregabalin respectively.
Date of approval -21 August 2023

Always take **LYNERIG** exactly as your doctor has instructed you. You should check with your doctor or pharmacist if you are unsure. Your doctor will tell you how long your treatment with **LYNERIG** will last. If you have the impression that the effect of **LYNERIG** is too strong or too weak, talk to your doctor or pharmacist.

The usual recommended starting dose for **LYNERIG** is 75 mg twice daily (150 mg/day), with or without food. This dose may be increased to 150 mg twice daily after an interval of 3 to 7 days **LYNERIG** is for oral use only.

If you are an elderly patient (over 65 years of age), you should take **LYNERIG** normally except if you have problems with your kidneys. You must discuss this with your doctor.

Your doctor may prescribe a different dosing schedule and/or dose if you have problems with your kidneys.

Swallow the capsule whole with water.

If you take more LYNERIG than you should

In the event of over dosage, consult your doctor or pharmacist. If neither is available, contact the nearest hospital or poison centre.

Applicant/PHCR: AUROGEN SA (PTY) LTD
Product proprietary name: LYNERIG
Dosage form and strength Each capsule contains 25/75/150 mg of Pregabalin respectively.
Date of approval -21 August 2023

You may feel sleepy, confused, agitated, or restless as a result of taking more **LYNERIG** than you should. Fits have also been reported.

If you missed a dose of LYNERIG

If you forgot to take a dose, take it as soon as you remember unless it is nearly time for your next dose. Do not take a double dose to make up for forgotten individual doses.

4. Possible side effects

LYNERIG can have side effects.

Not all side effects reported for **LYNERIG** are included in this leaflet. Should your general health worsen or if you experience any untoward effects while taking **LYNERIG**, please consult your healthcare provider for advice.

If any of the following happens, stop taking **LYNERIG** and tell your doctor immediately or go to the casualty department at your nearest hospital if someone experiences symptoms of respiratory problems because these can be life threatening.

Symptoms to watch for include:

- Confusion or disorientation,
- Unusual dizziness or lightheadedness,
- Extreme sleepiness or lethargy
- Slowed, shallow, or difficult breathing
- Unresponsiveness, which means the person does not answer or react normally or when you wake them up,

Applicant/PHCR: AUROGEN SA (PTY) LTD
Product proprietary name: LYNERIG
Dosage form and strength Each capsule contains 25/75/150 mg of Pregabalin respectively.
Date of approval -21 August 2023

- Bluish-coloured or tinted skin, especially on the lips, fingers, and toes
- inflammation of the eyes (keratitis) and a serious skin reaction characterized by rash, blisters, peeling skin and pain)

These are all very serious side effects. If you have them, you may have had a serious reaction to **LYNERIG** . You may need urgent medical attention or hospitalisation.

Tell your doctor immediately or go to the casualty department at your nearest hospital if you notice any of the following: The following side effects occur frequently:

- jaundice (yellowing of the skin and eyes), nausea, abdominal pain, fatigue and fever
- decreased urinary output, swelling of your legs ankles and feet
- dark, reddish urine, a decreased amount of urine, weakness and muscle aches

These are all serious side effects. You may need urgent medical attention.

Tell your doctor if you notice any of the following:

Frequent side effects:

- Nausea, vomiting,
- diarrhoea constipation, flatulence,
- feeling bloated,
- dry mouth,

Applicant/PHCR: AUROGEN SA (PTY) LTD

Product proprietary name: LYNERIG

Dosage form and strength Each capsule contains 25/75/150 mg of Pregabalin respectively.

Date of approval -21 August 2023

- increased appetite,
- mood changes, confusion, irritability, disorientation,
- difficulty sleeping,
- decreased libido.
- dizziness, excessive sleepiness, headache
- symptoms of ataxia which can be impaired balance and coordination, slurring, coordination abnormal, tremor,
- dysarthria, amnesia, memory impairment, disturbance in attention,
- tingling or prickling sensation (paraesthesia), reduced sense of touch or sensation (hypoesthesia),
- sedation, balance disorder, lethargy,
- blurred vision, double vision,
- vertigo (spinning sensation),
- muscle cramp, muscle pain, back pain, spasm
- erectile dysfunction
- changes in the way you walk, fall, feeling fatigued.
- weight gain

Less frequent side effects:

- Low white blood cell count, leaving you prone to infections,
- decreased blood sugar levels,
- anorexia
- seeing, feeling or hearing things that are not there.

Applicant/PHCR: AUROGEN SA (PTY) LTD

Product proprietary name: LYNERIG

Dosage form and strength Each capsule contains 25/75/150 mg of Pregabalin respectively.

Date of approval -21 August 2023

- panic attack, restlessness, agitation, depression, depressed mood, elevated mood, aggression, mood swings, depersonalisation, word finding difficulty, abnormal dreams,
- increase libido, inability to orgasm,
- lack of interest or enthusiasm,
- impulsive behaviour, lack of restraint
- temporary loss of consciousness,
- abnormal movement of lips and face, jerky movements of the muscles
- dizziness postural, intention tremor,
- uncontrolled movements of the eye,
- mental impairment, speech disorder
- absent reflexes,
- loss of taste function of the tongue,
- feeling unwell
- convulsions,
- loss of ability to detect smell,
- decreased body movement,
- Learning disability in the form of poor writing,
- Peripheral vision loss, visual disturbance, eye swelling, visual field defect, eye pain,
- Eye strain, experiencing flashes of light in the field of vision,
- dry eye,
- increase flow of tears, eye irritation

Applicant/PHCR: AUROGEN SA (PTY) LTD

Product proprietary name: LYNERIG

Dosage form and strength Each capsule contains 25/75/150 mg of Pregabalin respectively.

Date of approval -21 August 2023

- Vision loss, inflammation of the cornea,
- altered visual depth perception, pupil dilation, visual brightness,
- hearing sensitivity,
- slow, fast, irregular or abnormal heartbeat, heart problems,
- increase or decrease in blood pressure, hot flushes feeling cold
- shortness of breath, cough, nasal congestion and dryness, snoring,
- collection of fluid in the lungs,
- difficulty swallowing, swelling of the tongue, increased saliva production, heartburn, numb around mouth
- Muscle twitching, joint swelling, muscle stiffness, pain including muscle pain, neck pain.
- delayed ejaculation
- menstrual cramps, irregular menstruation, breast pain, breasts discharge and enlargement
- development of breasts in males
- chest tightness, pain, fever, thirst, chills, abnormal physical weakness or lack of energy
- Changes in blood and liver test results (blood creatinine phosphokinase increased, alanine amino transferase increased, aspartate aminotransferase increased, platelet count decreased, neutropenia, increase in blood creatinine, decrease in blood potassium)
- increased bleeding tendency
- low blood platelet count, resulting in severe bleeding

Applicant/PHCR: AUROGEN SA (PTY) LTD
Product proprietary name: LYNERIG
Dosage form and strength Each capsule contains 25/75/150 mg of Pregabalin respectively.
Date of approval -21 August 2023

- nosebleeds
- dry mouth
- indigestion
- inflammation of the liver
- joint pain, aching muscles including muscle cramps.
-

Frequency unknown side effects:

- Suicidal ideation and Suicidal behaviour

If you notice any side effects not mentioned in this leaflet, inform your doctor or pharmacist.

Reporting of side effects

If you get side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects via the " 6.04 Adverse Drug reaction Reporting Form found online under SAHPRA's publications

https://www.sahpra.org.za/documents/86422f1b6.04_ARF1_Jul16_v4.pdf. By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store LYNERIG

Store at or below 25 °C.

Keep the blisters in the carton until required for use.

Keep HDPE containers tightly closed.

Applicant/PHCR: AUROGEN SA (PTY) LTD
Product proprietary name: LYNERIG
Dosage form and strength Each capsule contains 25/75/150 mg of Pregabalin respectively.
Date of approval -21 August 2023

STORE ALL MEDICINES OUT OF REACH OF CHILDREN.

Return all unused medicine to your pharmacist.

Do not dispose of unused medicine in drains or sewerage systems (e.g. toilets).

6. Contents of the pack and other information

What LYNERIG contains

LYNERIG contains the active substance pregabalin. The other ingredients of **LYNERIG** are:

- Maize starch Ph.Eur
- Talc Ph.Eur
- Empty hard gelatine capsule shell

LYNERIG 25 mg:

1. Constituents of the capsule:

The capsule shell contains:

- Gelatine,
- Sodium lauryl sulphate
- Water
- Titanium dioxide (C.I. No: 77891 and E No: E 171).

2. Constituents of the printing ink:

- The printing ink contains:

Applicant/PHCR: AUROGEN SA (PTY) LTD
Product proprietary name: LYNERIG
Dosage form and strength Each capsule contains 25/75/150 mg of Pregabalin respectively.
Date of approval -21 August 2023

- Shellac
- Dehydrated Alcohol
- Isopropyl alcohol
- Butyl Alcohol
- Propylene Glycol
- Strong Ammonia solution
- Black Iron oxide (C.I. No: 77499)
- Potassium hydroxide
- Purified water

LYNERIG 75 mg:

1. Constituents of the capsule:

The capsule shell contains:

- Gelatine,
- Sodium lauryl sulphate
- Water
- Titanium dioxide (C.I. No: 77891 and E No: E 171)
- Iron oxide red (E No: 172)

2. Constituents of the printing ink:

The printing ink contains:

- Shellac
- Dehydrated Alcohol
- Isopropyl alcohol
- Butyl Alcohol
- Propylene Glycol
- Strong Ammonia solution

Applicant/PHCR: AUROGEN SA (PTY) LTD
Product proprietary name: LYNERIG
Dosage form and strength Each capsule contains 25/75/150 mg of Pregabalin respectively.
Date of approval -21 August 2023

- Black Iron oxide (C.I. No: 77499)
- Potassium hydroxide
- Purified water

LYNERIG 150 mg:

1. Constituents of the capsule:

The capsule shell contains:

- Gelatine,
- Sodium lauryl sulphate
- Water
- Titanium dioxide (C.I. No: 77891 and E No: E 171)

2. Constituents of the printing ink:

The printing ink contains:

- Shellac
- Dehydrated Alcohol
- Isopropyl alcohol
- Butyl Alcohol
- Propylene Glycol
- Strong Ammonia solution
- Black Iron oxide (C.I. No: 77499)
- Potassium hydroxide
- Purified water

WHAT LYNERIG looks like and contents of the pack LYNERIG 25 MG:

Applicant/PHCR: AUROGEN SA (PTY) LTD
Product proprietary name: LYNERIG
Dosage form and strength Each capsule contains 25/75/150 mg of Pregabalin respectively.
Date of approval -21 August 2023

Capsules, hard. white cap / white body, size '5' hard gelatine capsule shells, imprinted with "z" on cap and "10" on body with black ink contains white to off-white granular powder.

The dimensions of the size '5' capsules are as follows:

LENGTH:

6.2±0.4 mm for the cap,

9.3±0.4 mm length for the body

WIDTH:

4.91±0.03 mm for the cap

4.65±0.03 mm for the body

LYNERIG 75 MG:

Capsules, hard. orange cap / white body, size '4' hard gelatine capsule shells, imprinted with "z" on cap and "12" on body with black ink contains white to off-white granular powder.

The dimensions of the size '4' capsules are as follows:

LENGTH:

7.2±0.4 mm for the cap,

12.2±0.4 mm length for the body

Width:

5.33±0.03 mm for the cap

5.06±0.03 mm for the body

LYNERIG 150 mg:

Capsules, hard. White cap / white body, size '2' hard gelatine capsule shells, imprinted with "Z" on cap and "14" on body with black ink contains white to off-white granular powder.

The dimensions of the size '2' capsules are as follows:

Applicant/PHCR: AUROGEN SA (PTY) LTD
Product proprietary name: LYNERIG
Dosage form and strength Each capsule contains 25/75/150 mg of Pregabalin respectively.
Date of approval -21 August 2023

Length:

9±0.4 mm for the cap,

15.2±0.4 mm length for the body

Width:

6.37±0.03 mm for the cap

6.08±0.03 mm for the body

LYNERIG 25 mg

1) Blister Pack:

Capsules are packed in an aluminium foil blister pack.

Pack size: 60's – Each carton contains 6 blisters of 10 capsules each.

2) HDPE Pack:

Capsules are packed in white opaque round 40 mL HDPE bottle.

Pack size: 60's – One HDPE container contains 60 capsules.

LYNERIG 75 mg

1) Blister Pack:

Capsules are packed in an aluminium foil blister pack.

Pack size: 60's – Each carton contains 6 blisters of 10 capsules each.

Applicant/PHCR: AUROGEN SA (PTY) LTD
Product proprietary name: LYNERIG
Dosage form and strength Each capsule contains 25/75/150 mg of Pregabalin respectively.
Date of approval -21 August 2023

2) HDPE Pack:

Capsules are packed in white opaque round 60 mL HDPE bottle.

Pack size: 60's – One HDPE container contains 60 capsules.

LYNERIG 150 mg

1) Blister Pack

Capsules are packed in an aluminium foil blister pack.

Pack size: 60's – Each carton contains 6 blisters of 10 capsules each.

2) HDPE Pack:

Capsules are packed in white opaque round 75 mL HDPE bottle.

Pack size: 60's – One HDPE container contains 60 capsules.

**NAME, BUSINESS ADDRESS AND TELEPHONE NUMBER OF THE HOLDER OF THE
CERTIFICATE OF REGISTRATION**

Aurogen SA (Pty) Ltd
Woodhill Office Park, Building 1, First Floor
53 Phillip Engelbrecht Avenue
Meyersdal, Ext. 12
1448, Johannesburg South Africa

Registration number

LYNERIG 25 mg

48/2.5/1067

LYNERIG 75 mg

48/2.5/1068

Applicant/PHCR: AUROGEN SA (PTY) LTD
Product proprietary name: LYNERIG
Dosage form and strength Each capsule contains 25/75/150 mg of Pregabalin respectively.
Date of approval -21 August 2023

LYNERIG 150 mg

48/2.5/1069

This leaflet was last revised in

21 August 2023